Genmab — Marts 2024
-
Vi har altså været på vej op lige siden 13 og 14 feb. Tillod mig at skrive det netop den 13.02, og at jeg købte Bull den dag i området 1834 (se chatten hvis nogen tvivler). Købte flere Bull igen umiddelbart inden månedsskiftet. Det er fuldkommen naturligt, at vi har nedture, men trenden er op, og har været det i over en måned. Lige nu konsoliderer denne trend sig, og næste step er at vi bliver ovre de ca 2130. Det sker! uanset evt udsving på vej op. På lidt sigt skal vi langt højere
Min syn! -
European Lung Cancer Congress 2024 - Amivantamab - https://oncologypro.esmo.org/content/search?search[searchText]=Amivantamab &search[date]=month&search[sort]=date_desc
-
FDA Fully Approves AbbVie's Elahere For Ovarian Cancer https://www.proinvestor.com/investornyt/1135920/fda-fully-approves-abbvies-elahere-for-ovarian-cancer
-
Bibob og JKY. Det satser vi på
-
14-18.000 aktier opkøbes daglig https://www.proinvestor.com/investornyt/1136150/transactions-in-connection-with-share-buy-back-program
-
Regeneron har problemer i CD20XCD3.
-
-
Abstract 509: The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer https://aacrjournals.org/cancerres/article/84/6_Supplement/509/737622/Abstract-509-The-MPS1-TTK-inhibitor-NMS-01940153?searchresult=1
-
Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE
NHL-1 trial https://aacrjournals.org/cancerres/article/84/6_Supplement/5071/736959/Abstract-5071-Minimal-residual-disease-MRD-status?searchresult=1 -
-
UBS analyst Xian Deng Reiterates Buy Rating on Genmab A/S (PT 2800) https://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+Genmab+AS+(GEN%3ADC)+(GMAB)/22976308.html
-
Aktier/middag: Mærsk til bunds efter broulykke i USA - Genmab og Danske topper https://www.proinvestor.com/investornyt/1136612/aktier-middag-maersk-til-bunds-efter-broulykke-i-usa-genmab-og-danske-topper
-
Lidt speciel kommentar fra foregående link: Genmab ligger øverst på grund af lidt nyt fra USA, hvor FDA's rådgivende komite skal mødes. Vi ved ikke, om det handler om Genmab og selskabets nye produkt, det har på vej, Hexabody CD38, men det er der bare meget, der tyder på, at det gør, siger Lars Hytting.
Så deeeet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind